Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
Merck Sharp & Dohme,Pembrolizumab,"Melanoma, Resected Stage III, Adjuvant treatment",Pembrolizumab (Keytruda),,,Oncology Agents and Immunosuppressants
